Market revenue in 2023 | USD 159.3 million |
Market revenue in 2030 | USD 158.6 million |
Growth rate | -0.1% (CAGR from 2023 to 2030) |
Largest segment | Quantitative |
Fastest growing segment | Digital |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Quantitative, Digital, End-point |
Key market players worldwide | Abbott Laboratories, Qiagen NV, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Thermo Fisher Scientific Inc, GE Aerospace, BioMerieux SA, Roche Holding AG ADR, Fluidigm Corporation |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to real time pcr, digital pcr, and end point pcr market will help companies and investors design strategic landscapes.
Quantitative was the largest segment with a revenue share of 85.19% in 2023. Horizon Databook has segmented the Spain real time pcr, digital pcr, and end point pcr market based on quantitative, digital, end-point covering the revenue growth of each sub-segment from 2018 to 2030.
The rising prevalence of chronic diseases in Spain, such as cancer, is expected to be the key factor propelling market growth. According to the World Cancer Research Fund (WCRF) International, in 2022, around 260,455 newly diagnosed cancer cases were recorded in the country.
It is estimated that the number of cancer cases is likely to rise due to the increasing life expectancy in the country. The rising incidence of chronic diseases and the growing awareness regarding early diagnosis are expected to propel the use of PCR technologies.
The outbreak of COVID-19 increased the demand for qPCR products for diagnostic purposes amid the pandemic. To address the rising demand, local players developed and introduced new products. For instance, in March 2020, GENOMICA SAU, a Spanish company of PharmaMar Group, received CE certification for CLART COVID-19.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain real time pcr, digital pcr, and end point pcr market , including forecasts for subscribers. This country databook contains high-level insights into Spain real time pcr, digital pcr, and end point pcr market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account